| Business Summary | | Maxim
Pharmaceuticals
Inc.
is
a
late-stage
biopharmaceutical
company
developing
advanced
drugs
and
therapies
for
cancer,
infectious
diseases,
degenerative
diseases
and
topical
disorders.
The
Company's
lead
drug
candidate
Ceplene
(histamine
dihydrochloride,
formerly
known
as
Maxamine),
is
designed
to
improve
immunotherapy
by
protecting
critical
immune
cells,
and
is
administered
in
combination
with
cytokines.
The
Company
is
also
developing
MaxDerm,
a
Ceplene-related
series
of
drug
candidates
for
the
treatment
of
certain
topical
disorders.
Furthermore,
through
its
proprietary
high-throughput
screening
technology,
the
Company
has
identified
compounds
that
may
serve
as
inhibitors
and
activators
of
caspases,
key
enzymes
that
modulate
and
carry
out
the
cellular
signaling
pathways
involved
in
programmed
cell
death,
also
known
as
apoptosis. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | MAXM
develops
novel
therapeutics
for
the
treatment
of
cancer
and
infectious
diseases.
Its
lead
drug,
Ceplene,
is
designed
to
facilitate
an
immune
system
mechanism
to
achieve
full
anti-tumor
and
anti-infection
potential.
For
the
six
months
ended
3/01,
revenues
totalled
$1.7
million,
up
from
$288
thousand.
Net
loss
applicable
to
Com.
decreased
9%
to
$22.7
million.
Revenues
reflect
the
licensing
of
anti-cancer
compounds.
Lower
loss
benefitted
from
the
absence
of
preferred
dividend. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
827;
after
tax
earnings
were
-6,429. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Larry Stambaugh, 53 Chairman
of Directors, Pres and CEO | $515K | -- | Dale Sander, 41 CFO,
VP-Fin., Sec. | 264K | $956K | Kurt Gehlsen, Ph.D., 44 VP
of Devel. and CTO | 310K | 1.4M | Geoffrey Altman, 39 VP
of Marketing and Sales | 190K | -- | Dollar
amounts are as of 30-Sep-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|